Gilead(US:GILD) ZACKSยท2024-09-24 23:06Company Performance - Gilead Sciences closed at $83.79, with a -0.24% change from the previous session, underperforming the S&P 500's gain of 0.25% [1] - The stock has increased by 9.13% over the past month, contrasting with the Medical sector's loss of 1.51% and the S&P 500's gain of 1.65% [1] - The upcoming earnings report is projected to show earnings per share (EPS) of $1.66, a decrease of 27.51% year-over-year, with expected quarterly revenue of $6.98 billion, down 0.98% from the previous year [1] Fiscal Year Estimates - For the entire fiscal year, earnings are projected at $3.78 per share, representing a -43.75% change from the prior year, while revenue is expected to be $27.63 billion, reflecting a +1.9% change [2] - Recent revisions to analyst forecasts are important as they indicate short-term business trends, with positive revisions seen as a favorable sign for the company's outlook [2] Valuation Metrics - Gilead Sciences has a Forward P/E ratio of 22.23, which is higher than the industry average of 21.46, suggesting it is trading at a premium [3] - The company has a PEG ratio of 2.91, compared to the industry average PEG ratio of 2.21, indicating a higher valuation relative to projected earnings growth [3] Industry Context - The Medical - Biomedical and Genetics industry, part of the Medical sector, holds a Zacks Industry Rank of 80, placing it in the top 32% of over 250 industries [4] - The Zacks Industry Rank measures the strength of industry groups, with the top 50% rated industries outperforming the bottom half by a factor of 2 to 1 [4]